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In the  preceding  study,  mutant  Rous  sarcoma virus 
(RSV)  proteases  are  described  in  which  three  amino 
acids found in the human immunodeficiency virus-1 
(HIV-1) protease (PR) were  substituted  into  structur- 
ally comparable  positions  (Grinde, B., Cameron, C. E., 
Leis, J., Weber, I., Wlodawer, A., Burstein,  H.,  Bizub, 
D., and Skalka, A.  M. (1992) J. Biol. Chem. 267, 
9481-9490). In this report, the activity of the wild 
type  and  these  mutant  PRs  are  compared  using  a set of 
RSV  NC-PR  peptide substrates with single amino  acid 
substitutions  in  each  of  the P4 to P3’ positions. With 
most substrates,  the relative activities of  the two active 
mutants  followed  that of  the  RSV  PR. Substitutions  in 
the P1 and P1’ positions were an exception; in this 
case, the mutants behaved more like the HIV-1 PR. 
These results confirm  predictions from structural  anal- 
yses which  indicate  that  residues 106 and 106 of  the 
RSV PR are important in forming the S1 and S1’ 
binding  subsites.  These results, further  analyzed  with 
the aid of computer modeling of the RSV PR with 
different  substrates,  provide  an  explanation  for  why 
only  partial  HIV-1 PR-like behavior was introduced 
into  the  above RSV  PR mutants. 
Crystal structures of two retroviral proteases (PRs)’ are 
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The abbreviations used are: PR, protease; RSV, Rous sarcoma 
virus; AMV, avian myeloblastosis virus; HIV, human immunodefi- 
ciency virus; NC, nucleocapsid. Amino acids and numbers  written  in 
italics refer to  the HIV-1  PR. 
currently available. These include the native  structure of the 
RSV PR, refined at 2-A resolution ( l ) ,  and three separate 
structures of the HIV-1 PR, refined at 2.7-3-A resolution. In 
addition, several structures of HIV-1 PR with various sub- 
strate-based  inhibitors bound in the active site  are available 
(2-9). In the present study, crystallographic information has 
been extended by molecular modeling to predict the structure 
of the RSV PR with bound substrate  in order to investigate 
the molecular basis of specificity. 
Peptides that contain sequences corresponding to known 
target  sites on retroviral precursor polyproteins can be  cleaved 
precisely by these retroviral PRs in uitro. The main determi- 
nants of specificity reside in  7 amino acids of the substrates 
(10, 11) extending from P4-P3’ (notation according to 
Schechter and Berger (12)). Despite wide differences in pref- 
erence for substrate,  a detailed comparison of the  structural 
data  and sequence alignments has indicated that most HIV-1 
PR amino acid residues in  contact with substrate-based pep- 
tide  inhibitors  are remarkably conserved in the RSV  enzyme. 
Only 3 residues, at RSV PR positions 65,  105, and 106, are 
significantly different (13). In order to  test  the significance of 
these differences, mutant RSV PRs were constructed where 
these residues in the RSV PR binding site were changed to 
those of the HIV-1  PR. Since the  PR is a homodimer, muta- 
tions introduced into the monomeric subunit are de facto 
double mutations  in the native PR. Analysis of two of these 
mutants, R105P,G106V and H65G,R105P,G106V, indicated 
that both enzymes showed a preference for a peptide substrate 
based on the reverse transcriptase-integrase cleavage site  in 
the HIV-1 precursor protein (13). In  this  report, we present  a 
more detailed analysis of the differences in substrate  inter- 
actions caused by these mutations. A peptide substrate based 
on the  NC-PR cleavage site in the RSV polyprotein was used 
for this purpose. This substrate was cleaved with similar 
efficiencies by both the AMV and  HIV-1 wild type PRs  as 
well as  the  mutant RSV PRs (13). The activity of the two 
mutant and two wild type PRs were examined using 40 
different peptide substrates with single amino acid changes 
placed in the  P4 through the P3’ positions. Results from this 
analysis show that amino acid substitutions in the PR at 
positions 105 and 106,  which are primarily part of the  S1 and 
S1‘ enzyme subsites, cause changes which affect almost ex- 
clusively the recognition of the P1 and P1’ substrate positions. 
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EXPERIMENTAL  PROCEDURES 
Bacterial  Cells and DNA Constructs-Bacterial  growth conditions, 
the expression vector used for mutagenesis, pPR, and preparation  of 
purified  RSV PRs containing the H65G and R105P,G106V and 
R105P,G106V,H65G substitutions from an inclusion body fraction 
derived from Escherichia coli, were as described previously (13-15). 
Preparation of HIV-1 PR, also from E. coli, and avian myeloblastosis 
virus (AMV) PR, from virions, has been described (16,  17).  The RSV 
and AMV PRs, which differ by 2 amino acids in primary  structure 
and are enzymatically indistinguishable, have been used interchange- 
ably in these studies. 
Peptides-Peptides were synthesized and purified to at least 95% 
purity  by  Advanced ChemTech (Louisville, KY). Peptides were char- 
acterized as described  by  Grinde et al. (13). All of these peptides were 
readily soluble in water. 
Proteolytic Assay and Kinetic Analysis-The PR assay and kinetic 
analysis were as previously described (13-15). 
Molecular  Modeling-Atomic coordinates of RSV PR (1, 18) and 
HIV-1 PR with inhibitor (6) were examined on an Evans and Suth- 
erland PS390 computer graphics system using the program  FRODO 
(19). 
RESULTS 
Molecular  Modeling of the Flaps of the RSV PR-Several 
residues, including N61 to G69, from one subunit  and A59’ 
to G69’ from the  other subunit  in each flap of the RSV PR 
dimer are  not visible in the crystal  structure  and  are consid- 
ered to be disordered. (Note  that  the prime notation in this 
context is used to denote the second subunit of the PR dimer.) 
Since the flap region is presumed to be very important for 
substrate binding and catalysis, and  crystal  structures of the 
RSV PR complexed to ligand are not available, we have 
modeled the structure of the RSV PR flaps based on the co- 
crystal structure of HIV-1 PR with the inhibitor MVTlOl 
(6). The C, atoms of the RSV PR dimer were superimposed 
on those of HIV-1 PR with inhibitor  as described by Weber 
(20). Subsequently, the aligned structures  and sequences (13) 
were examined in the flap region, and  the missing residues 
were modeled (Fig. 1). There are 3 additional residues to 
accommodate in the flap of RSV PR compared to HIV-1 PR. 
In the structures of HIV-1  PR with ligands, the ends of the 
two flaps overlap and are linked by hydrogen bonds. In 
addition, the ends of both flaps interact with the inhibitor. It 
thus appeared unlikely that  the extreme ends of the flaps 
could be extended by the 3 extra residues in  the RSV PR. 
Also, a sequence alignment of the two enzymes showed many 
identical residues for the overlapping ends of the flaps (from 
I64 to 171, on either side of the centrally placed 150). There- 
fore, RSV PR sequences IHGIGGGI were modeled in the 
same positions as HIV-1  PR IGGIGGFI (Fig. 2). This included 
several conserved glycine and isoleucine residues, the straight- 
forward removal of the phenylalanine side chain of residue 53 
to form G70, and  the change of G48 to H65. The side chain 
of H65 was  modeled as lying on the surface of the flap and 
extended across to  the  other  strand of the antiparallel /3 pair 
where it may  form a hydrogen bond with the carbonyl oxygen 
of glycine 69. H65 may stabilize the flap by interacting with 
G69 or it may interact with a  substrate. 
The additional 3 residues, N61 to Q63, were placed in a 
small surface loop connecting A60 and I64 in a continuous 
chain in which bond lengths were  idealized. This leads into 
the established structural  parts of the RSV PR flaps around 
residues 59 and 60. Comparison of the subunit  structures of 
HIV and RSV PRs showed that small extensions of surface 
turns are common in RSV PR, while HIV PR has a more 
compact structure. One example of such a small insertion is 
provided by residues 7 and 8 of RSV PR, which extend as  a 
surface loop. It is not clear why this enzyme has such extended 
surface features, although removal of several of the larger 
surface loops has been shown to drastically reduce the  cata- 
lytic activity of the PR (13). The region leading to  the flap, 
from residue 46, differs in conformation between RSV and 
HIV-1 PRs. Again, the RSV PR has two additional small 
surface loops compared to  the same region in HIV-1 PR. 
The flap was first modeled in one subunit  and  then  a copy 
was rotated into the corresponding position in the other 
subunit of the dimer so that  it superimposed on the HIV-1 
PR second flap. The RSV PR dimer with modeled flaps is 
shown in Fig. 1. The modeled flap compared with the flap of 
the crystal  structure of the HIV-1  PR with inhibitor is shown 
in Fig. 2. Once the flaps were built, it was  possible to place a 
peptide substrate in a position similar to  that of the HIV PR 
substrate-based inhibitors. Only the amino acid side chains 
were altered to model most of the substrate. It was not obvious 
how to position the scissile peptide bond between P1 and P1’ 
since the inhibitors have a reduced bond or a hydroxyl (rep- 
resenting a  transition  state analog) instead of the carbonyl 
oxygen  lying near the catalytic aspartate residues. It appeared 
that a peptide bond between P1 and P1’ would  be under strain 
due to  the conformation of the substrate from P3 to P1 and 
P1’ to P3‘. Therefore, no attempt was made to position this 
carbonyl oxygen accurately. The conformation of the main 
chain of the substrate was not changed, but  the side chain 
conformations were adjusted when necessary to fit into  the 
appropriate subsite. The model of the  substrate is shown in 
Fig. 3. 
RSV  PR Subsites Deduced by Modeling the Flaps and Sub- 
strate-In HIV-1  PR, the inhibitors  are bound by a series of 
hydrogen bond interactions. There is a  set of conserved inter- 
actions between PR and main chain C=O and NH groups of 
the peptide substrate found in all available crystal structures 
(4-8). Also, each substrate side chain lies in a  separate subsite 
or pocket in the PR dimer. In some cases, substrate side 
chains may participate  in hydrogen bond or ionic interactions 
with amino acid residues lining the PR subsites. Equivalent 
RSV PR residues form the subsites and have the  potential for 
hydrogen bond interactions with the main chain of the sub- 
strate or inhibitor. The interactions with the main chain 
peptide groups are independent of the substrate sequence, 
and energy calculations suggest that these  contribute about 
58% of the total  substrate binding energy.’ 
A complete set of main chain hydrogen bond interactions 
is presented in Table I. These interactions  are equivalent to 
those predicted for HIV-1 PR with bound substrate (21). In 
addition, each substrate side chain provides sequence-depend- 
ent  interactions within individual subsites. These are mainly 
hydrophobic interactions, although in some cases hydrogen 
bonds or ionic interactions may be possible, as seen in the 
different co-crystal structures of HIV-1  PR with inhibitors. 
A list of amino acids predicted to form each RSV PR subsite 
is presented in Table 11. Several residues contribute to more 
than one subsite and  there is also some symmetry seen in the 
subsites on either side of the scissile bond. For example, 
subsites involving P2 and P2’ are similar. The residues inter- 
acting with a  substrate side chain will depend upon the size 
of the side chain, since a longer side chain can contact subsite 
residues further away. 
The overall features of each of the enzyme subsites pre- 
dicted from the model are as follows. Subsite S4 is on the 
protein surface such that a variety of residues might be 
accommodated in the P4 position of substrate. Subsite S3 is 
polar, formed partially by the charged residues, R10’ and 
R105’. P2 is found in a smaller hydrophobic subsite while 
subsite S1 can accommodate large hydrophobic amino acid 
C. Sansom and I. Weber, unpublished data. 
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FIG. 1. Structure of the RSV PR with substrate. A ,  ribbon drawing of the polypeptide backbone of the 
model for RSV PR with substrate in the center in a line drawing. B, the position of the mutations  in relation to 
the modeled flaps. Stereo view of the C, backbone of the crystal structure of the RSV PR dimer with the two 
subunits  in thick and thin lines. The C, atoms of the modeled flaps are shown in dashed tines, residues 61 to 69 in 
one subunit and 59 to 69 in  the other. The PR is labeled every 20 residues, and a prime indicates residues in  the 
second subunit. The position of the mutations is indicated by the residue present  in the wild  type: H65, R105, and 
G106 in a ball and stick representation  in one subunit only for clarity. 
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FIG. 2. Modeled flaps of the RSV 
PR. Stereo view  of the atoms in the 
modeled portion, residues 61 to 69, of 
one flap of RSV PR (thick lines) com- 
pared to  the structurally equivalent part 
of the HIV-1 PR flap from the crystal 
structure with inhibitor (thin or dashed 
lines). H65 is indicated and the side 
chain was modeled as interacting with 
residue 69 on the other strand of the 
flap. 
FIG. 3. Modeled substrate. Substrate residues P4 to P3’ from 
the model based on the co-crystal structures of HIV-1 PR with 
inhibitors. 
TABLE I 
Potential hydrogen bond interactions 
between substrate and protein 
Substrate position Hydrogen  bond PR residue” 
P4 c=o * * NH H65 
P3 NH * * *  0 D41 
c=o * * NH D41 
P2 NH * * *  o=c H65 
c=o * HzO * * NH I67 
P1 NH * * *  o=c G39 
c=o * * 0 D37 
P1‘ NH * * .  0 D37’ 
C=O * *  HzO ‘ *  MI 167’ 
P2’ NH . . .  o=c G39’ 
c=o * * * NH D41’ 
P3’ NH - . .  o=c H65‘ 
c=o . . . NH H66’ 
Amino acids in bold are  in the flaps. Prime indicates amino acids 
found in the second subunit. 
residues. Subsite S1’ has a relatively medium-sized, hydro- 
phobic pocket. In fact, the  natural substrates do not show a 
residue larger than leucine or histidine at Pl’. Subsite S2‘, 
like S2, is smaller and hydrophobic. Subsite S3’ lies near the 
dimer surface, and  the charged residues D41, H65, R10, and 
R105 contribute to  it. 
TABLE I1
Amino acids in the substrate binding pocket of the RSV PR in 
proximity to the substrate 
Subsite  Amino  acid“ 
S4 RlO’, D41,142, P62,Q63, R105’, H7’, m, M73 
s 3  RlO‘, D 4 1 , m ,  RlOS‘, L35’, G66,167, V104’, G106, 
S2 A40,144,164, H65, G66, I67’, 142, M73,1108, GllO 
s1 L35’, D37’, G39,G66, H65,167, V104’, R105’, G106’, 
1108‘ 
~107’ .  r1nw 
S1’ D37; G39’, w, 1108, R10, L35, D37’, H65’, 167, 
S2’ G39’, A40’, 144’. I64’, H65‘, 167, D41’, I42’, 171’, 
S3’ D41’, I64’, H65’, R105, R10, V104, R111’ 
I ””
I67’, V104,  R105,  G106,  S107 
M73’, V104’, 1108” - - 
Residues with atoms within 5 A of the C, or Co of the substrate 
are in bold type. Residues with atoms between 5  and 10 A from the 
C, of substrate  are in normal type. These residues were chosen since 
they  are on the aide of the side chain  rather than nearer the main 
chain of the substrate. They are also predicted to form the distal 
portions of the various subsites. Underlined residues indicate that 
they  are  in the flaps. The prime denotes that  the amino acid is derived 
from the second subunit. 
Using the above  model, we have noted that RSV PR resi- 
dues 105 and 106 and  the identical residues 105’ and 106‘ in 
the second subunit of the homodimer form the roof of subsites 
S1 and Sl‘, but  are also near subsites S3 and S3‘. His-65 and 
-65‘, which are in the flaps, are predicted to be associated 
with several subsites (Table 11). These residues are also in- 
volved in hydrogen bonding to  the P4, P3’, and P2 backbone 
carbonyl or amide groups in the substrate  (Table  I). 
Strategy-In a previous investigation (13), a series of mu- 
tant RSV PRs was constructed that substituted the amino 
acid found in the HIV-1  PR into the analogous location in 
the RSV PR (positions 65, 105, and 106). Analysis of these 
mutant PRs (R105P,G106V and H65G,R105P,G106V) indi- 
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cated that they  had  a 10- to 20-fold increase in  activity toward 
a substrate based  on an  HIV-1 cleavage site compared to  the 
RSV wild type PR. Therefore, an effort was undertaken to 
investigate the change in substrate recognition caused by 
these mutations in more detail. To do so, a set of 40 peptide 
substrates was synthesized, each identical with the  NC-PR 
sequence except for single amino acid substitutions in one of 
the positions from P4  to P3’ which interact with the 7 enzyme 
subsites (S4-S3’) in the  substrate binding pocket. The choice 
of amino  acid substituted  into  the  NC-PR peptide was based 
on the above model and was designed to challenge predicted 
subsites with amino acids that were different from those found 
in the wild type  substrate. 
Activity of Wild Type PRs on Modified NC-PR Substrates- 
The specific activities of the AMV and  HIV-1  PRs with these 
40 peptides are summarized in Tables I11 and IV.  An exami- 
nation of these activity data indicates that the substrate 
binding pockets of the two PRs  can be distinguished by this 
set of peptides. This is observed with amino acid substitutions 
placed in  the P4,  P3,  P2, and P1 positions  (Table 111). Most 
substitutions placed in P4  and P2 positions were inactivating 
TABLE I11 
PR activities with NC-PR peptide substrates substituted 
at the P4 to PI oositions 
Protease  activityb 
None 




















































































28.0  37.7 
25.0  32.1 
10.1  34.3 
8.0  32.4 
2.3  33.8 
2.6  29.7 











5.6  51.0 
1.3 25.1 
The NC-PR  substrate  (PPAVSLAMTMRR) was modified with 
single-amino acid substitutions in the  P4  to  P1 positions as indicated. 
The amino acid in the wild type substrate for each position is 
indicated in the parentheses. 
* Activity with the purified AMV PR, HIV-1 PR,  and RSV mutant 
PR containing the R105P,G106V and  the H65G,R105P,G106V sub- 
stitutions was assayed as described under  “Experimental Procedures.” 
The activity data are expressed as  the initial  rate of turnover  in the 
presence of 100 PM substrate and measured as molecules of product 
formed per active enzyme dimer per min. 
TABLE IV 
PR activities with NC-PR peptide substrates  substituted 
at the PI ’ to P3’ positions 
Protease  activityb 
None 13.4  13.1  3.2  37.0 
P1’ (Leu) 
Arg 8.8 0.1 0.0 5.5 
Phe 5.6 4.8 1.8 24.0 
Gln 3.1 0.0 0.0 3.9 
Glu 2.7  0.2 0.1 1.1 
Gly 0.1  0.3 0.2 0.3 
P2‘ (Ala) 
Leu 1.0 0.7  0.6 11.4 
Ser 0.9 1.0 0.4 9.1 
His 0.4 0.4  0.5 2.3 
GlY 0.6 1.0 0.5 8.6 
Trp 0.0 0.0 0.0 0.0 
TY r 27.1 22.0 5.4  6.6 
GlY 0.9 0.1 0.0 0.0 
ASP 0.8 0.0 0.0 0.0 
P3’ (Met) 
Leu 4.5  4.9 1.2 14.5 
Asn 1.5 0.5 0.0 0.9 
“The NC-PR  substrate  (PPAVSLAMTMRR) was modified with 
single-amino acid substitutions in the P1’ to P3’ positions as indi- 
cated. The amino acids in the wild type substrate  are indicated in the 
parentheses. 
.. 
Activitv with the Durified  AMV PR.  HIV-1  PR.  and RSV mutant 
PR containing the Ri05P,G106V and  the H65G, R105P,G106V sub- 
stitutions were assayed as described under “Experimental Proce- 
dures.” The activity data are expressed as  the initial rate of turnover 
in the presence of 100 pM substrate  and measured as molecules of 
product formed per active enzyme dimer per min. 
for the AMV PR while they had little effect on the  HIV-1 
PR. A similar observation was made with substitutions at  the 
P3 position, except that some of these  amino acid substitu- 
tions resulted in a 2.5- to 3.5-fold stimulation  in  activity with 
the AMV enzyme while having little effect on the HIV-1 PR 
(Table 111). The increase in  activity observed with P3 substi- 
tutions for the AMV PR was the result of increases in  both 
affinity for binding substrate  and catalytic rate (Table V). 
Most  amino acid replacements at  the P1 position increased 
activity for the  NC-PR  substrate for both the AMV and HIV- 
1 PRs. In particular, when leucine was substituted at P1, 
there was an 11- and 6-fold increase in  activity for the HIV- 
1 PR  and AMV PR, respectively (Table 111). When trypto- 
phan was substituted at  the same position, there was a 3- and 
7-fold increase in activity for the HIV-1 PR  and AMV PR, 
respectively. Thus,  HIV-1  PR prefers leucine at  this position, 
while AMV PR prefers tryptophan. The increase in  activity 
with tryptophan  at P1 is due to  an increase in affinity for 
substrate  and  an increase in  catalytic rate for both enzymes 
(Table V). Increases in activity and binding affinity are also 
observed for a  peptide with leucine substituted at P1 for the 
AMV PR.  There did not appear to be a significant change in 
K ,  for the leucine-substituted substrate for HIV-1 PR. In- 
stead, there appears to be a  substantial increase in  catalytic 
rate (Table V). Substitutions  at  P1’  to P3’ generally produced 
substrates with lower activity for both enzymes (Table  IV). 
However, here again differences in activity between the two 
PRs can be noted with substitution of Phe  at P1’ or tyrosine 
at  P3’. 
Activity of Mutant PRs on Modified NC-PR Substrates- 
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TABLE V 
Kinetic data for NC-PR peptide substrates substituted 
ut the P3 and PI positions 
Proteaseb 
None 
Km 1.0 1.0 1.0 1.0 
k a t  1.0 1.0 1.0 1.0 
L t / K m  1.0 1.0 1.0 1.0 
P3 Arg 
Km 0.52 0.64 0.76 0.63 
Lt 2.6 2.2 6.9 1 .o 
kt/& 5.0 3.3 9.1 1.6 
P3 Phe 
K m  0.46 0.32 0.45 0.66 
k t  2.2 1.3 5.7 0.8 
kat /& 4.7 4.0 12.8 1.2 
P1 Trp 
Krn 0.23 0.19 0.27 0.33 
Lt 5.1 1.8 13.9 2.7 
L t I K m  21.8 9.4 51.5 8.1 
P1 Leu 
Km 0.42 0.22 0.3 1.1 
kcat 4.5 4.7 37.4 12.8 
k d K m  10.4 21.6 124.0 11.5 
P1 His 
Km 0.64 0.63 0.71 0.84 
kt 2.0 4.3 10.8 1.4 
Lt/Km 3.0 6.8 15.1 1.6 
P1 Gly 
K m  0.67 1.0 1.1 1.18 
Lt 0.12 0.24 0.32 0.68 
L t l K m  0.2 0.25 0.25 0.57 
a The NC-PR substrate  as  described in the legend to  Table I1 was 
modified at the P1 and P3 positions  as  indicated. 
‘The activity of the wild type AMV and HIV-1 PRs and  the RSV 
mutants  was  assayed, and K,,,, kat, and kat/K,,, values  were  calculated 
as described under “Experimental Procedures.” The K,,, values for 
the RSV, RSV R105P,G106V, RSV H65G,R105P,G106V, and HIV-1 
PRs were 48.5, 45.4, 76.8, and 15.8 PM, respectively,  for the NC-PR 
peptide.  The kat for the RSV, RSV R105P,G106V, RSV 
H65G,R105P,G106V, and HIV-1 PRs were 21.6, 19.9, 6.1, and 43.8 
min”,  respectively, for the NC-PR peptide.  The k., /K, ratio for the 
RSV, RSV R105P,G106V, RSV H65G,R105P,G106V, and HIV-1 PRs 
were 0.45, 0.44, 0.08, and 2.77 pW1 min”, respectively,  for  the NC- 
PR peptide.  The  kinetic  data  for  substituted  peptides are presented 
as the  relative  amount compared to that of the unmodified substrate. 
The activity of the R105P,G106V and the H65G,R105P, 
G106V  RSV PR mutants with the same set of modified NC- 
PR peptides is summarized in  Tables I11 and IV. In  P4  to P2 
and P2’ to P3’  substitutions, where the activity of the AMV 
enzyme was different from that of the HIV-1 PR,  the activity 
of the two mutants followed that of the wild-type AMV PR 
(Tables 111 and IV). For example, substitution of histidine, 
asparagine, and glycine, respectively, in the  P4 position re- 
sults  in  a progressive loss in activity for this  substrate for the 
wild type AMV PR and for both mutants (Table 111). In 
contrast,  these same substitutions increased the activity for 
this  substrate by the HIV-1  PR.  Similar conclusions, that  the 
mutants  PRs behave like the wild type AMV enzyme, can be 
drawn with arginine, phenylalanine, asparagine, histidine, 
and proline substitutions at P3; leucine, glycine, and  trypto- 
phan  substitutions at P2; leucine, serine, and glycine substi- 
tutions at P2’; and for tyrosine substitution at P3’. The other 
amino acid replacements described in Tables I11 and IV 
resulted in little  or no discrimination between the two PRs. 
Both  mutant  PRs behaved more like the HIV-1 PR when 
specific substitutions were placed at either the P1 or P1’ 
positions. This can be seen with P1’ substitutions of arginine, 
phenylalanine, and glutamine (Table IV)  which resulted in a 
PR substrate that was less active than wild type. However, 
arginine substitution at P1’ produced a substrate that had 
66% and 15% the activity for the AMV and HIV-1 PRs, 
respectively. The  mutant enzymes resembled the HIV-1 PR 
in that they  had very little detectable activity on this  substrate 
(Table IV). Substitution of tryptophan and leucine at P1 
produced the two most active substrates for both wild type 
PRs. Like the HIV-1 PR, both mutants preferred leucine 
rather  than tryptophan at  this position (Table 111). 
Substitution of histidine, glutamate, or arginine at P1 pro- 
duced substrates that were more active than wild type but 
less active than with either the tryptophan  or leucine substi- 
tutions.  Stimulation of activity with the AMV PR was ob- 
served to be 2- to 3-fold greater than with the HIV-1  PR. The 
mutant enzymes showed substantial activity with these sub- 
strates, making them appear in these cases more like the 
AMV PR. However, a kinetic analysis of the histidine substi- 
tution at P1 in the substrate indicated that  the increase in 
activity observed with the two mutants was due primarily to 
an increase in kc,, with very little effect on K,,, (Table IV). 
Also, the increase in kcat was 2- to &fold greater than observed 
with the AMV PR.  With  all of the modified peptides analyzed 
so far, changes in activity with the AMV PR have always 
resulted in alterations in both binding affinity and catalytic 
rate. The finding that there is little change in the binding 
affinity for the histidine-substituted substrate concomitant 
with a large change in catalytic rate suggests that  the  mutant 
enzymes more  closely resemble the HIV-1 PR rather  than  the 
AMV PR in their recognition of P1. As described above, 
leucine substitution  in P1 resulted in a very  large increase in 
kcat without much effect on the binding of substrate by the 
HIV-1 PR. It should also be pointed out that  the active sites 
in both  mutants  are hybrids derived from the parent enzymes 
and this may result in unique behavior with the various 
substrates. 
Comparison of Activities of the Double and Triple Mutant- 
Introducing the glycine at 65 with the proline at 105 and valine 
at 106 has a synergistic effect on activity with some but  not 
all P1-substituted peptides. This is seen directly with the 
tryptophan-  and leucine-substituted peptides where the activ- 
ity of the triple  mutant  is twice that of the sum of the activity 
of the double mutant  and  the H65G mutant alone (Table 111). 
These data are even more striking when  one takes into 
account that  the H65G,R105P,G106V mutant is actually 4 
times less active than  the R105P,G106V mutant on the un- 
modified NC-PR  substrate. Relative to  the activity observed 
with the wild type  NC-PR  substrate, the triple  mutant also 
has more activity than expected for other amino acid substi- 
tutions in P1. This is also true for at least 2 amino acids 
substituted in P3 positions (Table 111). 
A difference between the double- and triple-substituted 
mutants can also be seen by comparison of the kinetic data 
in  Table V. There  are very large increases in kcat for cleavage 
of the PI-substituted peptides compared to wild type sub- 
strates for the H65G,R105P,G106V mutant  that  are not ap- 
parent  for the R105P,G106V mutant. As argued above, the 
large effects on kc, are associated with the  S1  and S1’ subsites 
of the HIV-1 PR. 
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DISCUSSION 
A complete molecular model of the RSV PR dimer with 
substrate  bound  in  its  active  site  has  been developed. This 
was  accomplished  by combining  the  crystal  structure of the 
RSV PR with modeled flaps  and a substrate  based  on equiv- 
alent  structures of the HIV-1  PR complexed with  inhibitor. 
The positions of the  parts of the  flaps observed in  the  crystal 
structure of the RSV PR are more similar  to  the  equivalent 
parts of the HIV PR with inhibitor than they are to the 
structure of the  unliganded HIV PR. This suggested that  the 
RSV PR crystal  structure  is closer to  the conformation  with 
substrate  bound  than  the  corresponding  structure of the HIV- 
1 PR. This model was analyzed to predict both the amino 
acid residues forming the enzyme subsites that bind the 7 
substrate residues required for cleavage and the potential 
hydrogen bond interactions between the peptide substrate 
and enzyme. Similar  analyses of substrate or inhibitor  binding 
using molecular  models of HIV-2 PR have  been described (21, 
22). 
In order  to  test  the  predictions of RSV PR subsites, a series 
of NC-PR peptide substrates were synthesized with single 
amino acid substitutions  in  the P4 to  the P3’ positions.  The 
substituted  amino  acids were chosen to  challenge  individual 
subsites with amino acids that vary in size, charge, and 
hydrophobicity.  Glycine,  for instance, which has  no side 
chain, was substituted at each  position  to  test  the  importance 
of the side chain interactions in general. It has previously 
been  noted  that  there  is a structural  symmetry between sub- 
sites S3 and S3‘, S2 and S2‘, and S1 and Sl‘. Using the 
substituted NC-PR peptide  substrates,  it  has now been  shown 
that  these  paired enzyme subsites  are  functionally  asymmet- 
ric. This  is  demonstrated by the  substitution of asparagine in 
P3 and P3’ in  the NC-PR substrate, which results  in a 2.5- 
fold increase  and a 9-fold decrease in activity, respectively, 
for the wild type AMV PR. Other examples of asymmetry  can 
be  found  in  Tables I11 and IV as well. In general,  substitutions 
of amino  acids  in  the Pl’ ,  P2‘, and P3‘ positions  resulted  in 
loss of activity  for  both enzymes with  these  substrates.  The 
only exception is provided  by tyrosine  in P3’, which stimu- 
lates  activity by the AMV PR. 
Distinct differences can  be  seen  not only with  the  structur- 
FIG. 4. The effect of amino acid 
substitutions in the S1 enzyme sub- 
site. Stereo view of substrate residue P1 
in relation to the position of RSV PR 
residues R105’ and G106’ (continuous 
lines) or HIV-1 P R  residues P81’ and 
V82’ (doshed lines). The larger P1 tryp- 
tophan (continuous  lines) fits better in 
the RSV PR subsite S1, and  the smaller 
P1 leucine tits better in HIV-1 PR sub- 
site S1. This is because the side chains 
of P81’ and V82’ protrude  further into 
the subsite than R105’ and G106’. 
ally paired subsites, but between comparable subsites from 
the RSV and HIV-1  PRs. The  set of 40 modified RSV NC- 
PR substrates  distinguishes  the  substrate  binding pockets of 
the two PRs. This is most  clearly seen  in  the  data  presented 
in  Table 111. Substitutions of amino acids  in P4 and P3 have 
little effect on HIV-1 PR activity.  In  contrast,  substitutions 
of amino acids in P4 causes  significant losses in  activity for 
the AMV PR while substitutions  in P3 result  in a stimulation 
in activity for the  same enzyme. 
A comparison of the  substrate  binding pockets of RSV and 
HIV-1  PRs indicates  that 58% of the  amino acids are  con- 
served. This is much higher than  the 30% identity of residues 
found  when  comparing  the  total  structures of the two PRs. 
This suggests a hypothesis  that  the large  difference in  cata- 
lytic rate  and  substrate selectivity of the two  enzymes may be 
determined by a small  number of different  amino acid  residues 
in the substrate binding pockets. We have identified three 
such  amino  acids where  nonconservative substitutions exist. 
These  are H65, R105, and G106 in RSV PR compared to  the 
structurally  equivalent G48, P81, and V82 in HIV-1 PR. 
The residues R105,  R105’, (3106, and G106’ are  in a region 
that  is  seen clearly in  the  crystal  structure of each  subunit of 
the RSV PR. However, their relationship to the substrate 
must be deduced by modeling and comparison to inhibitor 
binding in HIV-1 PR crystal  structures. Residues 105 and 106 
form part of a  surface turn, involving  residues 104 to 108 from 
each subunit,  that  acts like a “roof” to  the  distal  portions of 
the S1 and S1’ subsites. Thus, changes in residues 105 and 
106 are  predicted  to affect  mainly binding of amino acids  in 
the P1 and P1’ substrate positions. The side chains of R105 
and R105’ also lie near  the  amino acid  side chains of residues 
in P3 and P3’. However, since R105 is directed  toward  the 
protein surface, these  interactions  are  predicted  to have  less 
of an effect on  the  substrate binding. Also, R105 and G106 
provide  a  large  pocket  for substrate side chains  at P1 and PI’. 
They do not form  hydrogen bond  interactions  with  the  main 
chain of the peptide substrate. By comparison, the proline 
and valine in  the HIV-1  PR and  in  the R105P,G105V mutant 
provide  a  more  hydrophobic environment for P1 and Pl’. The 
proline and valine side chains  protrude  into  the  subsites  and 
are  predicted  to  restrict  the  binding of very  large  side chains 
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at these substrate positions. As shown in Fig. 4 for PI ,  leucine 
binds well in  the smaller subsite formed by the HIV-1  PR, 
while tryptophan binds well in the larger subsite formed by 
the RSV PR.. 
H65 is found in the flap region and was positioned by 
modeling and alignment with G48 of HIV-1  PR (Fig. 2). The 
side chain of H65 was adjusted to form a hydrogen bond 
interaction with the carbonyl oxygen of G69 on the other 
strand of the two antiparallel p strands forming the flap. 
Therefore, H65 is predicted to help maintain the conforma- 
tion of the flap. In addition, the amide and carbonyl oxygen 
of H65 are expected to form hydrogen bond interactions with 
the substrate  (Table I) by exact analogy to G48 of HIV-1 PR. 
H65 and H65’ are predicted to be part of the S3 and S3’ 
subsites, respectively, and  they lie near the SI’ and S2 and 
S2’ enzyme subsites. Since H65 forms part of the same 
subsites as 105 and 106, additive effects may occur when all 
three amino acids are  present  in the substrate binding pocket. 
It does not seem surprising that altering H65 would inter- 
fere with catalysis since it is needed for both  maintaining the 
conformation of the flaps and for forming four hydrogen bond 
interactions with substrate. However, in the case of the triple 
mutant, when this  mutation is combined with the changes in 
105 and 106 in each subunit, the flaps apparently assume a 
near correct conformation that permits G65 to form hydrogen 
bonds with the substrate, resulting in an active enzyme. 
Nevertheless, this  interaction is not optimal, since the triple 
mutant has about one-fourth the activity of the wild type 
RSV PR on the NC-PR peptide substrate. This interaction 
can be improved by modifying the substrate. For example, 
when leucine is substituted for serine in  the P1 position of 
the RSV NC-PR substrate, the triple mutant, but not the 
double mutant,  exhibits twice the activity compared to wild 
type RSV PR. It is thus possible that  the side chain interac- 
tions introduced by substitution of leucine for serine bring 
the substrate sufficiently close to  the flap to  further  enhance 
the interaction between G65 and  substrate. 
A further analysis of the modified NC-PR substrate data 
indicates that both RSV mutants  exhibit behavior very similar 
to  the wild type AMV PR for substitutions in the P4, P3, P2, 
P2’, and P3‘ substrate positions. In contrast, the RSV mu- 
tants behave more  like the HIV-1  PR in preference for amino 
acids substituted in the P1 and P1’ positions (Tables I11 and 
IV). This result is understandable since the 105- and 106- 
positions of the RSV PR are associated primarily with the S1 
and S1’ enzyme subsites. 
These  results confirm the hypothesis that discrimination 
of substrate by PR is dependent upon side chain  interactions 
between amino acids in the enzyme subsites and  those  in the 
substrate. As long as the main chain hydrogen bonding to 
substrate remains intact,  then  the subsites can act independ- 
ently of one another in discrimination of substrates. This 
offers a logical explanation for why the exchange of amino 
acids at positions 65,  105, and 106 resulted in only a  partial 
expansion of substrate preference for the reverse transcrip- 
tase-integrase HIV-1 substrate (13). Thus, to more fully 
change the substrate preference of the RSV PR for HIV-1 
substrates and probably to increase the catalytic rate will 
require simultaneous amino acid exchanges in all seven of the 
enzyme subsites. 
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